A Phase 1 interventional study of sitagliptin phosphate in Liver Insufficiency, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-08-19.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hepatic Insufficiency by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Hepatic Insufficiency · Merck & Co., Inc.
Among the 10 studies in Hepatic Insufficiency by Merck & Co., Inc, this one is the 4th largest by enrollment, is the only one that started in 2004, is one of 10 in phase 1, and was the 1st registered.
113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.
Browse Hepatic Insufficiency studies →1 of the 10 studies in Hepatic Insufficiency by Merck & Co., Inc is open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC
Ages 18–75 · Healthy volunteers
Of the 10 Hepatic Insufficiency studies recruiting now, 3 (30%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.
Median enrollment 20 across the 10 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
1 of the studies in Hepatic Insufficiency by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05093972Merck Sharp & Dohme LLCUlonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) | 2027-06-29 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Hepatic Insufficiency by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to compare the plasma concentrations of MK0431 at different times in patients with hepatic insufficiency vs healthy control subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
Also known as: MK0431
the plasma and urine pharmacokinetic parameters of MK0431
Time frame: measured at predose, 0.5, 1,1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 24, 32, 48, 72 and 96 hours post dose
Side effects, physical exam, lab safety data, urging drug screen, ECG and vital signs
Time frame: throughout study and at 12 weeks
No study locations are listed for this record.
The record gives a start of Apr 2004, a primary completion of May 2004 and a completion of May 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin